2023-505801-17-00CompletedPhase 1
Pharmacokinetic comparison of efanesoctocog alfa vs other EHL-rFVIII products in participants with severe haemophilia A
Source: EU CTIS (euclinicaltrials.eu) · Last updated 1 Jun 2026
- Status (registry)
- Completed
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 36 (actual)
- First submitted
- 23 Nov 2023
- Start date
- 15 Jan 2025
- Lead sponsor
- Swedish Orphan Biovitrum AB (publ)
- Diseases
- Haemophilia
- EU CT number
- 2023-505801-17-00
What you commit to
- Study type: Interventional · Phase 1
- Participants enrolled: 36
- 9 sites in 4 countries
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study design.
Sites (9)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Specialized Hospital For Active Treatment Of Hematological Diseases EAD | Sofiya | Bulgaria | Completed |
| Universitaetsklinikum Bonn AöR | Bonn | Germany | Completed |
| Universitaetsklinikum Frankfurt AöR | Frankfurt Am Main | Germany | Completed |
| Complejo Hospitalario Universitario Juan Canalejo | A Coruna | Spain | Completed |
| Hospital Universitario Y Politecnico La Fe | Valencia | Spain | Completed |
| Hospital Unviersitario Miguel Servet | Zaragoza | Spain | Completed |
| Azienda Ospedaliero-Universitaria Careggi | Florence | Italy | Completed |
| Azienda Ospedaliera Universitaria Federico II Di Napoli | Naples | Italy | Completed |
| Humanitas Research Hospital | Rozzano | Italy | Completed |
This page is information, not medical advice. Discuss any trial with your doctor.